A Novel Sphingosine-dependent Protein Kinase (SDK1) Specifically Phosphorylates Certain Isoforms of 14-3-3 Protein*

Tamar MegidishDagger , Jonathan Cooper§, Lixin Zhang, Haian Fuparallel , and Sen-itiroh HakomoriDagger **

From the Dagger  Pacific Northwest Research Institute, Seattle, Washington 98122 and Department of Pathobiology, University of Washington, Seattle, Washington 98195, the § Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, and the  Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Protein kinases activated by sphingosine or N,N'-dimethylsphingosine, but not by other lipids, have been detected and are termed sphingosine-dependent protein kinases (SDKs). These SDKs were previously shown to phosphorylate endogenous 14-3-3 proteins (Megidish, T., White, T., Takio, K., Titani, K., Igarashi, Y., and Hakomori, S. (1995) Biochem. Biophys. Res. Commun. 216, 739-747). We have now partially purified one SDK, termed SDK1, from cytosol of mouse Balb/c 3T3(A31) fibroblasts. SDK1 is a serine kinase with molecular mass 50-60 kDa that is strongly activated by N,N'-dimethylsphingosine and sphingosine, but not by ceramide, sphingosine 1-phosphate, or other sphingo-, phospho-, or glycerolipids tested. Its activity is inhibited by the protein kinase C activator phosphatidylserine. Activity of SDK1 is clearly distinct from other types of serine kinases tested, including casein kinase II, the alpha  and zeta  isoforms of protein kinase C, extracellular signal-regulated mitogene-activated protein kinase 1 (Erk-1), Erk-2, and Raf-1. SDK1 specifically phosphorylates certain isoforms of 14-3-3 (eta , beta , zeta ) but not others (sigma , tau ). The phosphorylation site was identified as Ser* in the sequence Arg-Arg-Ser-Ser*-Trp-Arg in 14-3-3 beta . The sigma  and tau  isoforms of 14-3-3 lack serine at this position, potentially explaining their lack of phosphorylation by SDK1. Interestingly, the phosphorylation site is located on the dimer interface of 14-3-3. Phosphorylation of this site by SDK1 was studied in 14-3-3 mutants. Mutation of a lysine residue, located 9 amino acids N-terminal to the phosphorylation site, abolished 14-3-3 phosphorylation. Furthermore, co-immunoprecipitation experiments demonstrate an association between an SDK and 14-3-3 in situ. Exogenous N,N'-dimethylsphingosine stimulates 14-3-3 phosphorylation in Balb/c 3T3 fibroblasts, suggesting that SDK1 may phosphorylate 14-3-3 in situ. These data support a biological role of SDK1 activation and consequent phosphorylation of specific 14-3-3 isoforms that regulate signal transduction. In view of the three-dimensional structure of 14-3-3, it is likely that phosphorylation by SDK1 would alter dimerization of 14-3-3, and/or induce conformational changes that alter 14-3-3 association with other kinases involved in signal transduction.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Glycosphingolipids, sphingolipids, and their catabolites have been implicated as modulators of signal transduction processes (for reviews, see Refs. 1-5). Sphingosine (Sph),1 the backbone component of all sphingolipids, was originally discovered as an inhibitor of protein kinase C (PKC), in contrast to the stimulatory effect of diacylglycerol (DAG) (6). The inhibitory effect of D-erythro-Sph and its N-methyl derivative (N,N'-dimethyl sphingosine; DMS) on PKC was stronger than other Sph stereoisomers and Sph derivatives (7). Subsequent studies have demonstrated effects of Sph and DMS on various protein kinases. Sph inhibits calmodulin-dependent kinase (8) and insulin receptor tyrosine kinase (9), but enhances casein kinase II (CKII) (10). DMS strongly enhances kinase activity of epidermal growth factor receptor (11) and Src kinase (12).

Sph has been suggested as a second messenger, since its low level is increased upon stimulation of cells. Agonists such as platelet-derived growth factor and insulin-like growth factor, cause activation of ceramidase, an enzyme that converts ceramide to Sph and fatty acids, resulting in an increase in Sph levels (2, 13). Phorbol ester treatment of HL60 cells causes a 3-fold increase in Sph levels detected by chemical method (14). DMS is generated from Sph by an enzyme present in mouse brain (15), and mass spectrometric analysis indicated that DMS is a minor component relative to Sph in HL60 cell extract; these findings suggest a physiological significance for both Sph and DMS (16). Exogenous Sph stimulates tyrosine phosphorylation of focal adhesion kinase, paxillin, and Crk, and induces mitogenesis in Swiss 3T3 fibroblasts (2, 17-19). Sph also induces prominent phosphorylation of multiple endogenous proteins with molecular mass 18-165 kDa in Jurkat cell extracts, suggesting the existence of multiple substrates for Sph-activated kinases (20). Similar phosphorylation of multiple proteins occurs in the presence of Sph or DMS in both cytosolic and membrane extracts of mouse Balb/c 3T3(A31) fibroblasts (21). Phosphorylation is not stimulated by other lipids indicating existence of specific protein kinases highly activated by Sph or DMS, but not by ceramide, sphingosine 1-phosphate (Sph-1-P), or various other sphingolipids, phospholipids, and glycerolipids. Protein kinases activated by Sph and DMS are termed "sphingosine-dependent protein kinases" (SDKs). However, the number, identities, and substrates of these SDKs are unclear. Using amino acid sequencing, we have identified several cellular proteins that are phosphorylated in vitro by SDKs including the 14-3-3 isoforms beta , zeta , and tau  (21).

14-3-3 proteins comprise a family with a remarkable evolutionary conservation extending to lower eukaryotes and plants. There are seven distinct mammalian isoforms (beta , gamma , epsilon , zeta , eta , tau , and sigma ). 14-3-3 isoforms appear to modulate a large variety of functional proteins and enzymes, including lipid-activated kinases (22-24) such as PKC, Raf-1, and phosphatidylinositol 3-kinase, and other kinases or phosphatases involved in control of cell cycle, cell death, and mitogenesis (25-27). 14-3-3 proteins are thought to function as adaptor proteins that allow interaction between signaling proteins that do not associate directly with each other (25). The association of 14-3-3 with different kinases in cytosol and membrane may contribute to kinases activation during intracellular signaling (28, 29). Platelet-derived growth factor and insulin-like growth factor induce association of 14-3-3 with the death agonist BAD, preventing its interaction with the membrane bound death agonist, BCL-XL, and contributing to cell survival (30). These agonists also increase Sph level, suggesting a link between 14-3-3 and Sph signaling. The diverse effects of Sph and its derivatives on cell cycle progression, cell death, and mitogenesis, and the similarity between Sph biological effects and 14-3-3 protein functions, suggest that SDKs mediate the biological role of Sph through 14-3-3 phosphorylation.

Here we report purification of one type of cytosolic SDK (SDK1) which phosphorylates only certain isoforms (beta , eta , and zeta ) but not other isoforms (sigma  and tau ) of 14-3-3, or other proteins known to be substrates of other SDKs. We also identified the site at which SDK1 phosphorylates 14-3-3. Although the physiological significance of 14-3-3 phosphorylation is unknown, there is an interesting possibility that activation of SDK1 and consequent phosphorylation of 14-3-3, in combination with an increase in the intracellular levels of Sph or DMS, promotes or inhibits 14-3-3 dimerization, through which 14-3-3 activity is regulated.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials and Reagents

D-erythro-Sph (31), and N,N'-dimethyl-D-erythro-Sph (7) were synthesized chemically as described. Protein disulfide isomerase (PDI), TPA, and dithiothreitol (DTT) were purchased from Calbiochem (San Diego, CA). Columns with Q-Sepharose Fast Flow HR 10/10, Mono-S (HR 5/5), Mono-Q (HR 5/5), Sephacryl 200 (HR 10/30; for gel filtration), and phenyl-Sepharose HR 5/5 were purchased from Pharmacia Biotech Inc. (Pleasant Hill, CA). Molecular size standards for gel filtration were from Sigma. Leupeptin, aprotinin, pepstatin, trypsin inhibitor, 4-(2-aminoethyl)-benzene-sulfonyl fluoride (AEBSF), n-octyl-beta -glucoside, Triton X-100, Tween 20, and chemiluminescence kit were obtained from Boehringer Mannheim (Indianapolis, IN). [gamma -32P]ATP (specific activity 3000 mCi/mmol) was from NEN Life Science Products Inc. (Boston, MA). Recombinant bovine 14-3-3 zeta  isoform, and mutants Arg60-Glu and Lys49-Glu, were prepared as described (32). Expression and purification of recombinant 14-3-3 isoforms beta , eta , sigma , and tau , are described elsewhere.2 Recombinant PKM of PKCalpha , purified from Sf9 cells infected with baculovirus expressing recombinant human PKCalpha , was obtained from PanVera Corp. (Madison, WI). PKC antibodies (Abs), myelin basic protein, and prestained standards were purchased from Life Technologies, Inc. (Grand Island, NY). CKII assay reagents and its peptide substrate RRRDDDSDDD, and PKC assay reagents including myosin basic protein peptide corresponding to residues 4-14, NKRPSNRSKYL, were from Amersham. Reagents for SDS-PAGE, silver staining of SDS-PAGE, Bradford's for protein determination, and nitrocellulose (NC) membrane were from Bio-Rad. Dulbecco's modified Eagle's medium (DMEM) was from Irvine Scientific (Santa Ana, CA). Fetal bovine serum was from HyClone Laboratories (Logan, UT). T-Mat film (used for most experiments) and Bio-Max film (used for identification of phosphorylation site) were from Kodak (Tukwila, WA). Polyclonal Abs PAN specific to all 14-3-3 isoforms (catalog number sc-629), 14-3-3 zeta  (catalog number sc-1019), 14-3-3 tau  (catalog number 732), extracellular signal-regulated mitogene-activated protein kinase (Erk-1), and Erk-2 Abs were from Santa Cruz Biotechnology (Santa Cruz, CA). Raf-1 Ab was from Upstate Biotechnology Inc. (Lake Placid, NY). Ab to CKII was a generous gift from Dr. E. Krebs (University of Washington). Calreticulin was a generous gift from Dr. A. Helenius (Yale University).

Cell Culture and Stimulation with TPA

Confluent fibroblasts treated with TPA under serum-free conditions were used for purification of SDK1 from cytosolic extracts, since intracellular Sph level was increased while PKC activity was reduced under these growth conditions (33, 34). Mouse Balb/c 3T3(A31) cells (American Type Culture Collection, Rockville, MD) were cultured in DMEM supplemented with 10% fetal bovine serum, in a humidified atmosphere containing 10% CO2 and 90% air, at 37 °C. Number of passages was limited to five. Cells (5 × 105) were plated on 150-mm dishes, cultured for 6-8 days until confluence, washed 3 × with serum-free DMEM, incubated in the same medium for 3 h and then in DMEM containing 200 nM TPA in 0.01% dimethyl sulfoxide for 3-4 h. Next, cells were washed with ice-cold phosphate-buffered saline without Ca2+ and Mg2+, harvested, and kept frozen at -80 °C until utilized for enzyme purification.

Purification of SDK1

All purification procedures were carried out at 0-4 °C, and buffers used were filtered through membrane and degassed under vacuum immediately prior to column chromatography. The following buffer systems were used. Buffer A consisted of 20 mM Tris buffer (pH 8.5), 1 mM EDTA. Buffer B was Buffer A plus 10 mM DTT, 10 mM sodium fluoride, and 0.1 mg/ml AEBSF. Buffer C was Buffer A plus 10 mM DTT, 10 mM sodium fluoride, and 1 M KCl. Buffer D consisted of Buffer A with pH adjusted to 5.8-6.0, plus 10 mM DTT, 10 mM sodium fluoride, and 0.2% n-octyl-beta -glucoside. Buffer E was Buffer D with pH adjusted to 7.5 and Buffer F consisted of Buffer E plus 100 mM NaCl.

Step 1: Preparation of Cell Extract-- Aliquots of packed frozen cells (2.5 ml, 100 mg) were thawed on ice and suspended in 45 ml of homogenizing buffer consisting of 20 mM Tris (pH 7.5), 0.5 mM EDTA, 0.5 mM EGTA, 12 mM sodium fluoride, 10 mM beta -mercaptoethanol, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml trypsin inhibitor, 10 µg/ml pepstatin, 0.5 mg/ml AEBSF, and 5% glycerol. Homogenization was performed by 40 strokes in an ice-cooled, tight-fitting Dounce homogenizer. The homogenate was centrifuged at 500 × g for 10 min, and the supernatant was centrifuged at 100,000 × g for 60 min. The supernatant (cytosol) was subjected to further purification of SDK1, and activity was tested as described under "Standard SDK1 Activity Assay."

Step 2: Q-Sepharose Column Chromatography-- 45 ml of cytosolic fraction was mixed with 2.5 ml of 10% Triton X-100, agitated at 4 °C for 1 h, and immediately loaded on a Q-Sepharose column (1 × 10.5 cm) pre-equilibrated with Buffer B and washed with 4 volumes of Buffer B. In order to separate SDK1 activity from other kinases, proteins were then eluted by a combination of stepwise changes and linear gradient changes of NaCl concentration (0 to 1.0 M), as indicated by a dotted line in Fig. 1A. The linear gradients were from 0 to 0.2 M NaCl for 15 min, 0.2-0.35 M for 85 min, constant at 0.35 M for 33 min, 0.35-1 M for 24 min, and finally constant at 1 M for 18 min. Elution was performed at a flow rate of 0.5 ml/min, and 1.5-ml fractions were collected and subjected to standard SDK1 assay. Fractions containing SDK1 activity were pooled and dialyzed 4-6 h against 4 liters of Buffer A containing 10 mM beta -mercaptoethanol.

Step 3: Phenyl-Sepharose Column Chromatography-- A phenyl-Sepharose column was pre-equilibrated with Buffer C. KCl (final concentration 1 M) was added to the pooled fractions showing SDK1 activity at step 2 (after Q-Sepharose column chromatography). The pooled fractions were loaded on the phenyl-Sepharose column in Buffer C and washed with 4 column volumes of Buffer C. Proteins were eluted at a flow rate of 0.5 ml/min by decreasing KCl. The concentration was decreased from 1 to 0.5 M for 20 min, maintained at 0.5 M for 14 min, decreased from 0.5 to 0 M for 56 min (Fig. 1C), and 1-ml fractions were collected. Flow-through (FT) (unbound) fractions were pooled and dialyzed against 4 liters of Buffer A containing 10 mM beta -mercaptoethanol for at least 6 h.

Step 4: Mono-S Column Chromatography-- Dialyzed FT and bound phenyl-Sepharose fractions (diluted 4 times in buffer D) were passed separately through Mono-S column. SDK1 activity from both pools was eluted in FT fraction, and minimal SDK1 activity was bound to Mono-S.

Step 5: Mono-Q Column Chromatography-- Mono-S FT fractions of both pools were subjected to Mono-Q ion-exchange chromatography. A Mono-Q (HR 5/5) column was equilibrated with buffer E, and proteins were loaded at a flow rate of 1 ml/min. The column was washed with 6 ml of buffer E. In order to separate SDK1 activity from major PKC activity, elution was performed by applying a combined stepwise and linear gradient of NaCl (0 to 1.0 M) at a flow rate of 0.25 ml/min as indicated by the dotted line in Fig. 1D. The linear gradients were from 0 to 0.2 M NaCl for 10 min, constant at 0.2 M for 10 min, from 0.2 to 0.35 M for 30 min, constant at 0.35 M for 20 min, from 0.35 to 1 M for 10 min, and finally constant at 1 M for 10 min. Fractions (0.65 ml) were collected, and active fractions were pooled. Data obtained from the phenyl-Sepharose-bound pool is shown in Fig. 1D. A similar pattern was obtained from the phenyl-Sepharose-unbound pool (data not shown).

Step 6: Size Exclusion Chromatography-- In order to estimate the Mr of SDK1, a sample (0.5 ml) obtained from a Mono-Q column of phenyl-Sepharose-unbound pool was analyzed by gel filtration. The Sephacryl S-200 column (1 × 30 cm; total column volume 22.5 ml) was equilibrated with Buffer F. The sample was loaded at a flow rate of 0.5 ml/min for 3 min and eluted at a flow rate of 0.1 ml/min, and 0.5-ml fractions were collected. Standard SDK1 assay was performed, except that reactions were for 30 min in the presence of 1 µM ATP (1.4 × 105 cpm/pmol). Gel filtration protein standards beta -amylase (200 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), and cytochrome c (12.4 kDa) were fractionated immediately after SDK1 fractionation, and the Mr of SDK1 was estimated (Fig. 1E).

Standard SDK1 Activity Assay

Sph and DMS both activate SDK1; however, DMS was used for detection of SDK1 activity during purification since it cannot be metabolized to either ceramide or Sph-1-P. SDK1 activity during purification was estimated by standard assay utilizing 0.1 µg of 14-3-3 beta  and 100 µM DMS in 0.5% octyl-beta -glucoside. SDK1 activity required Mg2+ with optimal concentration of 15 mM (Mn was ineffective), and decreased as ionic strength increased. An IC50 of 150 mM NaCl was defined at purification steps 2 and 3. The total reaction volume of the standard assay system was 30 µl, i.e. 20 µl of substrate/kinase/sphingolipid mixture and 10 µl of ATP solution. The mixture contained 5- or 10-µl kinase fractions eluted from column chromatography (containing 5.0-0.02 µg of protein), 3 µl of 14-3-3 (1 µg of 14-3-3 in 50 mM Tris), 3 µl of 30 mM DTT, 6 or 1 µl of 50 mM Tris buffer (pH 7.5), and 3 µl of DMS (1 mM DMS in 5% octyl-beta -glucoside) or vehicle (5% octyl-beta -glucoside) alone. The reaction was initiated by addition of 10 µl of ATP solution consisting of 75 µM ATP, 45 mM magnesium acetate, and 2.5 µCi of [gamma -32P]ATP in 50 mM Tris-HCl (pH 7.5). The reaction mixtures were incubated at 30 °C for 15 min. The reactions were stopped by addition of 10 µl of 4 × concentrated Laemmli's SDS-PAGE sample buffer and heating at 100 °C for 10 min. Phosphorylation reactions were resolved on 12% SDS-PAGE, and gels were stained with Coomassie Brilliant Blue R-250 (0.1%) in 50% methanol and 10% acetic acid, destained, dried, and subjected to autoradiography for 1-24 h. Control assays were made using reaction without DMS, 14-3-3 substrate, or kinase. The 28-kDa band was excised and the amount of 32P incorporated into the 14-3-3 (28 kDa) substrate was determined by scintillation counting. SDK1 activity was calculated from the amount of 32P incorporated into the substrate, taking into account the specific activity of the radioisotope and reaction time. Values obtained from gel without phosphorylated protein (blank) were subtracted from each determination.

The substrate specificity of SDK1 toward 14-3-3 isoforms, 14-3-3 mutants, and other SDK substrates (PDI, calreticulin) were tested in the presence of 120 nM protein. Other lipids and vehicles were used as indicated in the figure legends.

Kinetic and Stoichiometric Analysis of SDK1 Activity

Kinetics of SDK1 activity were determined as explained in the Fig. 5, A and B. The stoichiometry of phosphorylation was estimated in order to determine how many moles of phosphate are incorporated in 1 mol of 14-3-3. The phosphorylation reactions were scaled up from 30 to 150 µl and assayed as above, except that 50 µl of purified SDK1, 2 µg of 14-3-3 zeta , and 500 µM ATP with specific activity of 7000 cpm/pmol were incubated for 4 h. To prevent depletion of the reaction components, 40 µl of mixture containing the same proportion of SDK1, DMS, DTT, and ATP as above was added after the first 2 h.

Determination of PKC and CKII Activity

The Ca2+- and phospholipid-dependent PKC activities present in cytosolic extract (5 µg) or fractions yielded from column chromatography (5 µl) were assayed by a modification of the method described previously (35), using a PKC assay kit (Amersham), that utilizes PKC-specific substrate (synthetic peptide MBP4-14) which is phosphorylated with the labeled phosphate group from [gamma -32P]ATP. Reactions were performed in the presence of kinase fraction and substrate, and in the presence or absence of kinase cofactors Ca2+ and PS/TPA. Samples (5 µl) were incubated in a buffer containing 50 mM Tris-HCl (pH 7.5), 90 µM peptide, 3 mM DTT, 1 mM CaCl2, L-alpha -phosphatidyl-L-serine (PS) dispersed in 0.3% Triton X-100 (8 mol % of Triton X-100), 2 µg/ml TPA, 15 mM magnesium acetate, and 100 µM ATP (containing 0.2 µCi of [gamma -32P]ATP) at 30 °C. After a 10-min reaction at 30 °C, radiolabeled peptide was separated from unincorporated 32P by binding to affinity phosphocellulose paper. Degree of phosphorylation was determined by liquid scintillation counting. Enzyme activity was calculated from the amount of 32P incorporated into the peptide, taking into account radioisotope specific activity and reaction time.

CKII activity present in cytosolic extract (5 µl) or fractions yielded from column chromatography was assayed by a modification of the method described previously (36) using a CKII assay kit (Amersham) with CKII specific substrate, a synthetic peptide. Samples (5 µl) were incubated in the presence of 250 µM peptide and 150 mM NaCl in 16 mM MOPS (pH 7.2), and reactions were initiated by addition of a mixture of 200 µM ATP, 10 mM MgCl2, and 0.2 µCi of [gamma -32P]ATP in 10 mM HEPES pH 7.5. After a 30-min incubation at 30 °C, radiolabeled peptide was separated from unincorporated 32P by binding to affinity phosphocellulose paper.

Chemical Synthesis of Hexadecapeptide Containing Phosphorylation Site

The peptide KNVVGARRSSWRVITT was synthesized by the Fmoc/PyBop method in 15 µmol scale utilizing a Shimadzu PSSM-8 synthesizer (Shimadzu Corp., Kyoto, Japan). Generated peptides were purified by preparative reverse phase high performance liquid chromatography on a C18 column (20 × 250 mm, Nakarai Tesque, Japan) at a flow rate of 10 ml/min, with a linear gradient of acetonitrile (0 to 60% for 45 min) in 0.1% trifluoroacetic acid, utilizing a Gilson auto-LC system (France). Purity and authenticity of the peptide was checked by reverse phase high performance liquid chromatography and electrospray ionization (ESI) mass spectrometry (ESI voltage -4.3 kV, scan range m/z 500-3000/3 s) utilizing a triple stage quadrupole mass spectrometer combined with ESI model bTSQ-700 (Thermo Quest Finnigan, San Jose, CA). Molecular ion m/z 1830 was detected together with additional sodium ion. This work was performed by Kimie Murayama and Tsutomu Fujimura, Central Laboratory of Medical Sciences, Juntendo University School of Medicine, Japan.

Phosphoamino Acid Analysis and Two-dimensional Phosphopeptide Mapping of 14-3-3 beta

One µg of 14-3-3 beta  was phosphorylated by SDK1 as described under "Standard SDK1 Activity Assay," except that the specific activity of [gamma -32P]ATP was 6.6 × 105 cpm/pmol. Reactions were continued for 90 min, and the products were separated on SDS-PAGE and transferred to NC membranes. Proteins were visualized by staining with Amido Black (0.2% (w/v) in methanol/acetic acid, 45:10) and subjected to autoradiography. The phosphorylated 14-3-3 band was excised, treated with 1% polyvinylpyrolidone-40 in 100 mM acetic acid at 37 °C for 1 h, washed 5 times with water, and digested with 10 µg of trypsin, endoarginylpeptidase (ArgC), or endolysylpeptidase (LysC) in 50 mM ammonium bicarbonate at 37 °C for 16-24 h. After the first 2 h, an additional 10 µg of protease was added to ensure complete cleavage. Peptides were recovered from NC membrane by washing in 20% acetonitrile, dried, washed with water, and dried 4 times to remove ammonium bicarbonate. 32P recovered in the supernatants from these digestions was 80, 70, or 50% for the three enzymes, respectively. For phosphoamino acid analysis, tryptic peptides were hydrolyzed in 6 N HCl at 110 °C for 2 h, and analyzed (37).

The digested peptides were subjected to two-dimensional phosphopeptide mapping (37). Briefly, the peptides were separated according to charge by electrophoresis at pH 1.9 at 1.2 kV for 25 min in the first dimension, followed by separation according to hydrophobicity by chromatography in 65% isobutyric buffer (10 h) in the second dimension. After visualization by autoradiography (Bio-Max film), 32P-labeled phosphopeptides were extracted from the cellulose plates in 200 µl (pH 1.9) of buffer by vortex, followed by centrifugation. Phosphopeptides in the supernatant were dried, washed 3 times with water, and subjected to either a second analytical digestion or manual sequencing by Edman degradation (37). The degradation products were resolved at pH 3.5 at 1.3 kV for 16 min, and visualized by autoradiography.

For performic acid oxidation, performic acid was prepared by mixing 10 µl of H2O2 (30%) in 90 µl of HCOOH (98%). The solution was incubated on ice for 1 h before use. Digested phosphopeptides were recovered from NC membrane, dried once, incubated in H2O2/HCOOH on ice for 2 h, washed, and analyzed as described above for unoxidized peptides.

In vitro Phosphorylation of Synthetic Peptide by PKM of PKCalpha

1 µl of solution containing 5.4 ng of PKM (specific activity, 800 fmol/min/ng) was incubated with 1 mM synthetic peptide in 14 µl of kinase buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM peptide, 3 mM DTT, 1 mM CaCl2, PS dispersed in 0.3% Triton X-100 (8 mol/% of Triton X-100), 2 µg/ml TPA, 15 mM magnesium acetate, and 1 µM ATP (containing 2 µCi of [gamma -32P]ATP) for 1 h at 30 °C. The synthetic peptide was omitted in control reaction. The phosphorylated peptide was separated from unreacted ATP by thin layer electrophoresis at pH 3.5, 1.6 kV, for 16 min. After visualization by autoradiography at room temperature for 10 min, phosphopeptides were extracted from the plate in pH 1.9 buffer and dried in a Speed Vac. The purified phophopeptide was digested with trypsin as described for phosphorylated 14-3-3 proteins.

Western Blotting with Isoform-specific Anti-14-3-3 Abs

Cell homogenates or samples obtained from column fractions were resolved on SDS-PAGE and transferred to NC membranes. The membranes were incubated at room temperature in 20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 3% bovine serum albumin, and 10% horse serum for 30 min, incubated with specific antiserum for 1-2 h, and washed. The blot was incubated with secondary Ab for 45 min, and developed with enhanced chemiluminescence. The PAN Ab was raised to a peptide found in all 14-3-3 isoforms, KSELVQKAKLAEQAERYDD, corresponding to amino acids 3-21 of human 14-3-3 beta . The zeta  Ab was raised to peptide CAGDDKKGIVDQSQQAY, corresponding to amino acids 134-149 of human 14-3-3 zeta . The tau  Ab was raised to peptide TSDSAGEECDAAEGAEN, corresponding to amino acids 229-245 of rat 14-3-3 tau . Mouse 14-3-3 theta  is identical to human 14-3-3 tau , and therefore these terms are used interchangeably in the literature (21, 38, 39); we will refer to them as tau . For Western blot analysis, 14-3-3 Abs and CKII Abs were used at 1:2000 dilution, kinase suppressor of ras (KSR) and PKC Abs at 1:1000 dilution, and Raf, Erk1, and Erk2 Abs at 1:500 dilution.

Immunoprecipitation and in Vitro Kinase Assay

Cells were homogenized with 40 strokes in Dounce homogenizer in lysis buffer containing TEN buffer (50 mM Tris, pH 7.5, 5 mM EDTA, 100 mM NaCl, and 50 mM sodium fluroide) plus 30 µg/ml leupeptin, 30 µg/ml aprotinin, 30 µg/ml trypsin inhibitor, 30 µg/ml pepstatin, 50 mM AEBSF, 0.5% Triton X-100. Proteins were solubilized by incubation at 4 °C for 30 min. Lysates were centrifuged in Eppendorf centrifuge at 4 °C for 15 min. The supernatant (6 mg) was diluted 1:2 in lysis buffer without Triton X-100 and 1 µg of anti-14-3-3 Ab was added at 4 °C. After 1 h, Protein A-agarose was added for 10-14 h. Immunoprecipitates were washed 2 times with TEN buffer containing 0.1% Triton X-100 at room temperature, 1 time with TEN buffer, and then incubated for 5 min at room temperature in TEN buffer containing 0.5% n-octyl-beta -glucoside and washed (this last step was repeated). The final wash was with 50 mM Tris and 50 mM NaCl. Pellets were resuspended in 150 µl of 50 mM Tris (pH 7.5) and 6 mM DTT. The suspension (15 µl) was subjected to standard SDK1 assay, except that DTT was not added, and reactions were performed in the presence of 1 µM ATP (1.4 × 105 cpm/pmol) for 30 min.

Metabolic 32P Labeling and Immunoprecipitation

3T3(A31) fibroblasts were incubated in phosphate-free DMEM containing dialyzed 10% fetal bovine serum for 3 h. The cells were labeled in serum-free, phosphate-free DMEM containing [32P]orthophosphate (0.045 mCi/ml) for 9 h. During the last 20 min cells were challenged with 2 or 10 µM DMS in 0.1% ethanol (stock 1 mM DMS was dissolved in 10% ethanol), or with 200 nM TPA. Cells were washed with phosphate-buffered saline without Ca2+ and Mg2+ and harvested with 0.5 mM EDTA at 4 °C. Cell viability was not affected under these conditions. Cells were sonicated in lysis buffer (10 mM Tris, pH 7.5, 5 mM EDTA, 50 mM sodium fluoride, 50 µg/ml leupeptin, 50 µg/ml aprotinin, 50 µg/ml trypsin inhibitor, 0.1 mg/ml AEBSF, 3 mM beta -mercaptoethanol, 1% Triton X-100), and incubated at 4 °C for 1 h for protein solubilization. Lysates were pelleted in an Eppendorf centrifuge at 4 °C for 15 min. Samples were denaturated at 70 °C for 30 min, centrifuged, and supernatants were diluted 1:4 in the above buffer containing 0.2 M NaCl, without Triton X-100. PAN anti-14-3-3 Ab complexed with immobilized Protein A/G (Santa Cruz) was added, and 14-3-3 was immunoprecipitated at 4 °C for 3 h. The immunoprecipitates were washed 3 times with TEN buffer containing 0.05% Tween 20 and once with buffer containing 50 mM Tris (pH 7.5) and 100 mM NaCl. Samples were resuspended in 2 times Laemmli sample buffer, separated by SDS-PAGE, and transferred to a NC membrane. Equal recovery of 14-3-3 proteins was confirmed by probing the filter with 14-3-3 Ab and enhanced chemiluminescence. Chemiluminescent substrate was removed by washing in 50 mM Tris (pH 7.5) and 100 mM NaCl, and by exposure to light for 1 h. The NC membrane was subjected to autoradiography to detect radioactive 14-3-3.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Purification and Separation of SDK1-containing Fraction-- SDK1 was purified by sequential column chromatography, and detected using 100 µM DMS as activator and 14-3-3 beta  as substrate (Fig. 1). SDK1 activity was eluted at 260-350 mM NaCl from a Q-Sepharose column at purification step 2 (Fig. 1A). SDK1 phosphorylated 14-3-3 beta , zeta , eta , and an endogenous 28-kDa protein, which was eluted between 300 and 350 mM NaCl (Fig. 1B). The 28-kDa protein most likely consists of 14-3-3 isoforms, since it was detected with PAN 14-3-3 Ab by Western blotting (data not shown). In some cases a minor SDK1 activity peak was eluted from the column at 0.1 M NaCl, without change in the elution pattern of the major SDK1 peak, which was purified further.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 1.   Sequential purification and chromatographic separation of SDK1 from PKC and CKII. Panel A, separation pattern of SDK1, PKC, and CKII activities through Q-Sepharoseion exchange column. This panel represents step 2 of the purification procedure. Proteins in cytosolic extract solubilized with Triton X-100 were loaded on Q-Sepharose column (1 × 10.5 cm), washed with Buffer B, and eluted at a flow rate of 0.5 ml/min with 0-1 M NaCl (combined linear and stepwise gradient). 5-µl aliquots of representative fractions were analyzed for SDK1, PKC, and CKII activities, and the amount of 32P incorporated into the substrates was quantified as described under "Experimental Procedures." Left ordinate, SDK1 activity (fmol/min). Near right ordinate, PKC and CKII activities (pmol/min). Dotted line, change in NaCl concentration (M; far right ordinate) during gradient elution. black-square, SDK1 activity tested with 120 nM (0.1 µg/30 µl) 14-3-3 beta  as substrate and 100 µM DMS in 0.5% octyl-beta -glucoside as lipid activator. , SDK1 activity toward 28-kDa protein identified as endogenous 14-3-3, tested without addition of 14-3-3 substrate. black-triangle, CKII activity. bullet , PKC activity tested in the presence of myelin basic protein peptide substrate, PS/TPA, and Ca2+. open circle , PKC activity tested in the absence of PS/TPA and Ca2+. Abscissa, selected chromatography fractions. Panel B, elution profile of SDK1 activity from Q-Sepharose column, indicated by autoradiogram of SDS-PAGE gel. The cytosolic extract (step 1) was treated before fractionation with 0.5% octyl-beta -glucoside instead of Triton X-100. The sample pH was increased to pH 8.5, and the sample was fractionated on a Q-Sepharose column equilibrated in buffer B containing 0.5% octyl-beta -glucoside (pH 8.5). Phosphorylation by the indicated fractions was analyzed in the presence of 120 nM 14-3-3 beta , eta , and zeta , or without addition of exogenous 14-3-3 ("endogenous substrates"). Dotted lines shown above the gels indicate change in NaCl concentration (M) during elution. Panel C, phenyl-Sepharose column chromatography of SDK1 activity. The salt concentration in SDK1 peak (31 ml) in panel A was adjusted to 1 M KCl, and proteins were loaded on a phenyl-Sepharose column (step 3). Bound proteins were eluted by decreasing the concentration of KCl from 1 to 0 M (dotted line; scale shown on right ordinate). black-square, SDK1 activity (fmol/min; scale shown on left ordinate). Right panel, levels of SDK1 activity toward human recombinant 14-3-3 beta  in the flow-through (lane FT) and in column fractions (5 µl) are shown in the autoradiogram of phosphorylation pattern induced in the presence of SDK1 and DMS. Arrow, position of 14-3-3 beta . These results are a representative example from at least four separate experiments. Panel D, separation of SDK1 activity from PKC by Mono-Q ion-exchange chromatography. The eluate from phenyl-Sepharose (step 3) was diluted 4 times and fractionated on Mono-S (step 4) followed by Mono-Q (step 5) equilibrated in Buffer E. Bound proteins were eluted by increasing the concentration of NaCl. Dotted line, change in NaCl concentration (M, far right ordinate) during gradient elution. 5-µl aliquots of representative fractions were used for standard SDK1 activity assay and for PKC activity assay. black-square, SDK1 activity (fmol/min; scale shown on left ordinate). bullet , PKC activity with complete assay system. open circle , PKC activity without PS/TPA and Ca2+ (indicated on near right ordinate in pmol/min). Right panel, autoradiogram of SDS-PAGE showing phosphorylated 14-3-3 beta  induced by SDK1 present in fraction before purification (load) and in representative eluted fractions (5 µl). +, activity in the presence of DMS. Activity in the absence of DMS (-) is shown for fraction 17. Panel E, estimated Mr of SDK1 by gel filtration analysis. A sample (0.5 ml) obtained from the Mono-Q column of phenyl-Sepharose-unbound pool was analyzed by gel filtration. Fractions (0.5 ml) were collected and SDK1 activity was assayed in aliquots (10 µl) of representative fractions. black-square, SDK1 activity was tested for 30 min. Scale (ordinate) is fmol. Arrows, positions of molecular weight standards (200, 66, 29, and 12.4 kDa). Right panel, autoradiogram of 12% SDS-PAGE of phosphorylated 14-3-3 beta  induced by SDK1 present in fraction before gel filtration (load) and in eluted fractions (5 µl) in the presence of DMS. Positions of molecular weight markers are indicated at right.

SDK1 activity was separated from some endogenous 14-3-3 by fractionation of the major SDK1 activity containing fractions on phenyl-Sepharose. SDK1 with low hydrophobicity, found in unbound phenyl-Sepharose pool, was separated from SDK1 with high hydrophobicity, bound to phenyl-Sepharose (Fig. 1C, fractions 11-17). Biochemical properties of SDK1 activities in both pools were examined by further purification on Mono-S followed by Mono-Q ion exchange chromatography. SDK1 activity that bound phenyl-Sepharose was eluted at 280-300 mM NaCl (fractions 9-16) (Fig. 1D). SDK1 activity obtained from unbound phenyl-Sepharose pools was eluted at 330-350 mM NaCl (data not shown). The kinase was finally isolated from minor contaminants by gel filtration (step 6). Purified SDK1 showed a sharp elution peak with molecular mass of 50-60 kDa on a gel filtration column (Fig. 1E).

Sph and DMS Are the Only Sphingolipids That Activate SDK1-- The effects of various concentrations of Sph and DMS delivered in ethanol or n-octyl-beta -glucoside, and their ability to activate purified SDK1 and consequently phosphorylate 14-3-3 zeta , were examined. Purified SDK1 was capable of phosphorylating 14-3-3 in the presence of Sph or DMS, but not in the presence of ethanol or n-octyl-beta -glucoside alone. Other controls lacking kinase or 14-3-3 failed to activate phosphorylation of 14-3-3 (data not shown). Very low concentrations (5 µM Sph or 25 µM DMS) were required for maximum SDK1 activation when ethanol was used as vehicle (Fig. 2A). A sigmoidal kinetic curve was observed when Sph or DMS were solubilized in ethanol for both 14-3-3 zeta  and beta  assay (data not shown). However, this phenomenon disappeared when the vehicle was changed from ethanol to n-octyl-beta -glucoside, and higher concentrations of Sph or DMS (100 µM) were necessary for SDK1 activation (Fig. 2B). The fact that 14-3-3 phosphorylation reached a plateau in the presence of n-octyl-beta -glucoside implies that this detergent prevents secondary effects, such as 14-3-3 dimerization or 14-3-3 oligomerization during SDK1 reaction. n-Octyl-beta -glucoside also increased SDK1 activity 5-fold relative to ethanol. These results suggest that Sph is the primary activator of SDK1 and that this activation is not mediated by a detergent effect. In contrast, SDK1 was not activated by other closely related sphingolipids such as Sph-1-P, C18-ceramide, PS, lyso-GM3, and oleoyl-lysophosphatidic acid (Fig. 2C).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of Sph, DMS, and other lipids on SDK1 activity. Panel A, effect of various concentrations of Sph (open circle ) and DMS (black-square) added in ethanol solution, on SDK1 activation and consequent phosphorylation of 14-3-3 zeta . Ordinate, activity expressed as femtomole of 32P incorporated into 120 nM 14-3-3 zeta , quantified as described under "Experimental Procedures." Abscissa, concentrations of Sph and DMS (µM). Lower panel, autoradiogram of SDS-PAGE of phosphorylated 14-3-3 zeta  induced by SDK1 activated by various concentrations (5, 25, 50, 100, 200, and 400 µM, indicated at the top) of Sph (six lanes on left) and DMS (six lanes on right) delivered in 1% ethanol solution. Arrow, position of 14-3-3 zeta . Panel B, effect of various concentrations of Sph (open circle ) and DMS (black-square) added in micellar solution of n-octyl-beta -glucoside, on SDK1 activation and consequent phosphorylation of 14-3-3 zeta . Lower panel, autoradiogram of the experiment performed with the same sphingolipid concentrations as in panel A. Axes, symbols, and units same as in panel A. Panel C, lipid specificity of SDK1. Autoradiogram of phosphorylated 14-3-3 zeta  (120 nM) incubated with purified kinase in the presence of 20 µM DMS, Sph-1-P, C18-ceramide, PS, lyso-GM3, or oleoyl-lyso-phosphatidic acid (lanes 1-6, respectively). These results are a representative example from at least four separate experiments.

Substrate Specificity of SDK1-- SDK1 was activated by DMS, resulting in phosphorylation of 14-3-3 beta , eta , or zeta , but not of sigma  or tau  (Fig. 3A). This trend was already evident in crude cytosolic fraction, and was unchanged after sequential chromatography including S200 column (purification step 6) (Fig. 3B). For the eta  isoform, the DMS requirement was less stringent than for beta  or zeta , as seen in various steps of purification (Fig. 3B). These results suggest that 14-3-3 eta  is phosphorylated by a kinase less sensitive to DMS, and that this kinase was removed by gel filtration on S200 column (step 6).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 3.   Substrate specificity of SDK1. Panel A, SDK1 phosphorylates 14-3-3 eta , beta , and zeta , but not 14-3-3 tau  or sigma . SDK1 activity is shown in cytosolic extract (left panel) and after purification on Q-Sepharose (step 2) (right panel), in the absence (-) and presence (+) of DMS. Panel B, substrate specificity of SDK1 indicated by phosphorylation of 14-3-3 beta , zeta , and eta  isoforms at various stages of purification. SDK1 was purified in five steps as described in the legend to Fig. 1: on Q-Sepharose, phenyl-Sepharose, Mono-S, Mono-Q, and S200 columns. Phosphorylation of beta , zeta , and eta , and endogenous substrate E induced by SDK1 at Q-Sepharose, phenyl-Sepharose, Mono-Q, and S200 gel filtration purification steps are shown in panels labeled at the top as Q-Seph, P-Seph, MonoQ, and S200, respectively. 14-3-3 isoforms used as substrates, and the absence (-) and presence (+) of DMS, are shown at the top of each lane. Panel C, SDK1 is an SDK that specifically phosphorylates 14-3-3 but not PDI or calreticulin. Partially purified SDK1 was incubated in the presence of 120 nM calreticulin (lanes 1-4), PDI (lanes 5-8), and 14-3-3 beta  in the absence (-) or presence (+) of 100 µM DMS delivered in 0.5% n-octyl-beta -glucoside. Equal amount of proteins were detected by Coomassie staining (data not shown). Positions of PDI, calreticulin, and 14-3-3 are indicated by arrows. Positions of molecular weight markers are indicated at left.

PDI and calreticulin were identified as substrates for cytosolic and membrane-bound SDK, respectively.3 However, SDK1 failed to phosphorylate PDI or calreticulin under the same conditions whereby 14-3-3 beta  was phosphorylated (Fig. 3C).

SDK1 Is a Kinase Distinct from CKII, PKCs, Erks, Raf, and Ca2+-dependent Kinases-- To determine whether SDK1 corresponds to known protein kinases, the elution profile of known kinases determined by either immunoblotting or specific kinase assay was compared with the elution profile of SDK1 activity. Ca2+- and phospholipid-dependent PKC activity (mostly PKCalpha ) and CKII activity were measured in fractions obtained by Q-Sepharose ion-exchange chromatography. CKII activity was completely separated from SDK1 activity by fractionation on a Q-Sepharose column (Fig. 1A). PKC activity partially overlapped SDK1 activity, but was completely removed after Mono-Q chromatography (Fig. 1ID). Abs to PKC alpha , Raf, and KSR did not recognize any proteins in SDK1 peak (data not shown). We further confirmed these results for SDK1 purified from cells before treatment with TPA. The elution pattern of SDK1 activity from the Q-Sepharose column was compared with elution of PKC zeta , Erk1, Erk2, CKII, and Raf, as determined by immunoblotting. PKC zeta , Erk1, Erk2, and CKII proteins were detected in some fractions; however, their antibodies lacked immunoreactivity with the SDK1 peak (Fig. 4A).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 4.   SDK1 is distinct from PKC isoforms, CKII, Erks, and Ca2+-dependent kinases. Panel A, SDK1 activity in fractions obtained from a Q-Sepharose ion-exchange chromatography of cell extract before treatment with TPA was compared with the elution of PKC zeta , Erk1, Erk2, CKII, and Raf proteins. Western blot analysis utilizing PKC zeta , Erk-1 and Erk-2, and CKII Ab (labeled at left) was performed on the fractions labeled in the top panel. Arrows, positions of kinases Erk-1 (44 kDa), Erk-2 (42 kDa), and CKII (two subunits with molecular mass 28 and 43 kDa). Downward arrow indicates SDK1-containing pooled fractions 11-18. Note that SDK1-containing fractions 11-18 do not contain any of these kinases. Panel B, PS is an inhibitor of SDK1. Partially purified SDK1 from TPA-treated cells (purification step 3, described in Fig. 1) was incubated in the absence (-) or presence (+) of 50 µM DMS delivered in 1% ethanol (lanes 1 and 2). The effects of Ca2+ (lanes 3 and 4), Ca2+ plus PS/TPA (lanes 5 and 6), PS (lanes 7 and 8), and DAG (lanes 9 and 10) on SDK1 activity were tested. PS or DAG were delivered in 1% ethanol while PS/TPA were dispersed in 0.3% Triton X-100. Arrow, position of 14-3-3 beta . Positions of molecular weight markers are indicated at left.

The SDK1 activity peak partially overlapped Ca2+-phospholipid-dependent PKC activity on Q-Sepharose or phenyl-Sepharose, but was separated on Mono-Q. To evaluate the possibility that SDK1 activity results from other Ca2+-phospholipid-independent PKC or Ca2+-dependent kinase activity, we studied the effect of the PKC activators PS, TPA, DAG, and Ca2+ on activation of SDK1. PS inhibited activation of SDK1 by DMS in the absence or presence of PKC activators Ca2+ and TPA (Fig. 4B). In contrast, DAG, Ca2+ (Fig. 4B), and TPA (data not shown) did not inhibit SDK1 activation in the presence of DMS. Taken together, these results indicate that (i) SDK1 activity is clearly distinguishable not only from PKC alpha , PKC zeta , CKII, Raf-1, Erk-1, Erk-2, and KSR, but also from Ca2+-dependent kinases; (ii) SDK1 is distinct from all PKC isoforms since its activity is inhibited by PS but not stimulated by PKC activators TPA, DAG, and Ca2+.

Kinetics of SDK1 Activity-- Reactions with various concentrations of 14-3-3 zeta  and SDK1 revealed a linear relationship between velocity of phosphorylation and quantity of both 14-3-3 and SDK1. The velocity of phosphorylation was positively correlated with substrate concentration (60-480 nM), without a plateau. However, when substrate concentration was 60 nM, the reaction was linear for higher concentrations of kinase (0-1000 ng) (Fig. 5A). Phosphorylation of 14-3-3 zeta  was very low at 44 °C and optimal at 30 °C (Fig. 5B). The velocity of phosphorylation was linear and positively correlated with reaction time (Fig. 5B). Stoichiometric analysis of 14-3-3 zeta  phosphorylation activated by SDK1 was performed using a large quantity of substrate, higher concentration of ATP, and prolonged incubation period (2-4 h). Approximately 55 and 60 pmol of 32P was incorporated into 60 pmol of 14-3-3 zeta  during 2 and 4 h incubation, respectively, and phosphorylation was completed after 4 h (Fig. 5C). Similar results were obtained in four separate experiments. These findings indicate that SDK1 phosphorylates only a single Ser residue in 1 mol of 14-3-3 monomer.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Kinetics and stoichiometry of SDK1 reactions. Panel A, kinetics of 14-3-3 phosphorylation activated by various quantities of SDK1 (nanograms are indicated on abscissa). Ordinate, femtomole of 32P incorporated into various concentrations of 14-3-3 zeta  (60, 120, 240, and 480 nM). Panel B, temperature dependence of SDK1 activity toward 120 nM 14-3-3 zeta . Ordinate, femtomole incorporated into substrate. Abscissa, phosphorylation at various times. black-square, 30 °C. bullet , 36 °C. open circle , 44 °C. Panel C, stoichiometry of 14-3-3 phosphorylation by SDK1 was determined by large scale phosphorylation in the presence of 14-3-3 zeta , DMS, and 500 µM ATP, and reactions were continued for 4 h. After 2 h SDK1, DTT, DMS, and ATP in Tris buffer were added as necessary to offset their depletion. The data presented are corrected for blank values obtained in the presence of the vehicle n-octyl-beta -glucoside. Stoichiometry was calculated using molecular mass 28 kDa for 14-3-3 zeta . Similar results were obtained in four separate experiments.

Identification of Phosphorylation Site-- In order to understand the molecular basis of SDK1 specificity toward particular 14-3-3 isoforms, we identified the phosphorylation site on 14-3-3 beta . 14-3-3 beta  was phosphorylated by SDK1 in the presence of DMS, and its phosphoamino acid content was determined. Phosphorylation occurred only at serine (Fig. 6A). A single phosphorylated peptide was released by trypsin digestion of phosphorylated 14-3-3 beta  (Fig. 6B). These results are consistent with the stoichiometric analysis indicating a maximum of 1 mol of phosphate/mol of monomer of 14-3-3, which suggestes a single phosphorylation site. The likely identity of this site was deduced from the following properties. First, performic acid oxidation of the tryptic digest gave four labeled phosphopeptides, indicating the presence of performic acid-susceptible amino acids (i.e. Cys, Trp, or Met) in the phosphopeptide (Fig. 6D). Second, digestion of phosphorylated 14-3-3 beta  with endoarginylpeptidase C (ArgC), which cleaves C-terminal to Arg, released the same phosphopeptide as trypsin, which cleaves C-terminal to Arg or Lys (Fig. 6C). In contrast, digestion of phosphorylated 14-3-3 beta  with endolysylpeptidase (LysC), which cleaves C-terminal to Lys, released different phosphopeptides with slower migration (data not shown). This suggests that Arg residues are closer than Lys residues on both sides of the phosphorylated Ser. Third, the tryptic phosphopeptide had a high positive charge-to-mass ratio at both pH 1.9 and 8.9 (data not shown), consistent with a small peptide containing more than one basic amino acid residue. Fourth, the first cycle of Edman degradation altered electrophoretic migration (Fig. 6E, lane 1), consistent with removal of basic residue. Labeled phosphate was released at the third cycle (lane 3), suggesting that the phosphoserine position is three residues from the trypsin and ArgC cleavage sites.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   Analysis of 14-3-3 beta  phosphorylation site. Panel A, phosphoamino acids (PAA) present in hydrolysate of tryptic digest of phosphorylated 14-3-3 beta . 14-3-3 beta  was phosphorylated by crude SDK1 (purification step 2), digested with trypsin, and acid hydrolyzed, and PAA analysis on two-dimensional electrophoresis was performed as described under "Experimental Procedures." The positions of PAA were determined by separation on cellulose thin-layer plates according to charge at pH 1.9 (horizontal axis) and pH 3.5 (vertical axis). The positions of phosphoserine (S), phosphothreonine (T), and phosphotyrosine (Y) standards were visualized with ninhydrin staining. Note that only phosphoserine was 32P-labeled. +, origin. Panels B-D, two-dimensional phosphopeptide mapping of 32P-labeled 14-3-3 beta  digested with trypsin (panel B) or endoarginylpeptidase (ArgC) (panel C). 14-3-3 beta  was 32P-phosphorylated by purified SDK1 (step 5, Fig. 1E) and analyzed as described under "Experimental Procedures." Panel D, labeled components 1, 2, 3, and 4 derived from performic acid oxidation of the single tryptic peptide indicated by arrow in panel B. In panels B-D, phosphopeptides were separated by electrophoresis at pH 1.9 (horizontal axis) and by chromatography (vertical axis) in hydrophobic buffer (65% isobutyric acid). Panel E, change of electrophoretic mobility of 14-3-3 beta  tryptic phosphopeptide and release of free phosphate upon the third cycle of manual Edman degradation. The 32P-labeled phosphopeptide was eluted from the TLC plate, subjected to manual Edman degradation, and products were separated by thin layer electrophoresis at pH 3.5 and visualized by autoradiography (Bio-Max film). Basic residue was released from the phosphopeptide upon the first cycle of Edman degradation, and a free phosphate (Pi) was released upon the third cycle. The origin is indicated by a line.

14-3-3 beta  contains one sequence consistent with the above findings. Phosphorylation of 14-3-3 beta  by SDK1 at Ser* in the sequence: Arg·-Arg-Ser-Ser*-Trp-Arg·-Val-, followed by tryptic cleavage at the positions bullet , would release a phosphopeptide with the observed properties. To test this prediction, a peptide Lys51-Asp-Val-Val-Gly-Ala-Arg-Arg-Ser59-Ser60-Trp-Arg-Val-Iso-Thr65-Thr66, corresponding to residues 51-66 of 14-3-3 beta , with Ser65 and Ser66 replaced by Thr, was synthesized. This peptide was phosphorylated in vitro, digested with trypsin, and analyzed in two-dimensional phosphopeptide mapping, in comparison with 14-3-3 beta  phosphorylated by SDK1.

The catalytic domain of PKC, PKM, was used to phosphorylate the synthetic peptide, since PKC has been shown to phosphorylate the Ser* residue in a similar synthetic peptide (40). SDK1 phosphorylates this synthetic peptide with low stoichiometry (less than 1% of the peptide present in the reaction was phosphorylated), suggesting that other structural features of the 14-3-3 protein play a role in recognition by SDK1. Amino acid analysis of the phosphorylated synthetic peptide revealed that it was phosphorylated on Ser but not on Thr, and labeled phosphate was released at the third cycle of Edman degradation (data not shown). Comparison of tryptic digest of 14-3-3 beta  phosphorylated by SDK1 with tryptic digest of the phosphorylated synthetic peptide showed that these peptides are identical (Fig. 7, A-C). Taken together, these results confirm that SDK1 phosphorylates 14-3-3 beta  at Ser60.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 7.   Ser linked to Trp in the sequence Arg-Ser-Ser-Trp-Arg is the phosphorylation site in 14-3-3 beta . Comparison of two-dimensional maps derived from two phosphopeptides analyzed under identical conditions. The two phosphopeptides were: (i) tryptic phosphopeptide derived from 32P phosphorylation of 14-3-3 beta  catalyzed by SDK1 as in Fig. 6B; (ii) tryptic phosphopeptide Arg-Ser-pSer-Trp-Arg (RSpSWR) derived from 32P phosphorylation of a synthetic peptide catalyzed by PKM. Panel A, the tryptic phosphopeptide was prepared from 32P-phosphorylated 14-3-3 beta  catalyzed by SDK1 (purification step 5) in the presence of 100 µM DMS in micellar solution of 0.5% n-octyl-beta -glucoside. Phosphopeptide was recovered from NC membrane by digestion with trypsin, and aliquot (1000 cpm) was analyzed as in Fig. 6B. Panel B, the synthetic peptide KNVVGARRSSWRVITT was phosphorylated by PKM, purified, and digested with trypsin as described under "Experimental Procedures." The resulting phosphopeptide (1000 cpm) was analyzed by two-dimensional mapping. Panel C, equal counts of synthetic phosphopeptide (500 cpm) (RSpSWR) were spotted together with the tryptic phosphopeptide (500 cpm) recovered from phosphorylation of 14-3-3 beta  by SDK1, and analyzed by two-dimensional mapping. Panel D, comparison of amino acid sequences surrounding SDK1 phosphorylation site in beta , eta , and zeta  isoforms of 14-3-3, and the corresponding sequences in tau  and sigma  isoforms. The phosphorylation sites Ser60, Ser59, and Ser58 in beta , eta  and zeta  isoforms, respectively, are shown in boldface. The corresponding residue in tau  and sigma  isoforms is Ala; these isoforms are therefore not phosphorylated by SDK1.

Comparison of the amino acid sequences of 14-3-3 beta , eta , zeta , tau , and sigma  isoforms indicates that the target site for SDK1 is present in 14-3-3 beta , eta , and zeta  (residue numbers Ser60 in beta , Ser59 in eta , and Ser58 in zeta ). The residue which replaces this Ser in tau  and sigma  is Ala (Fig. 7D). Thus, the 14-3-3 isoform specificity of SDK1 is attributable to the primary sequences of the different isoforms. The sequence Arg-Ser-Ser*-Trp-Arg fits the consensus motif for both protein kinase A (PKA) and PKC phosphorylation sites (41). However, PKA did not phosphorylate 14-3-3 (data not shown). PKC isoforms phosphorylate 14-3-3 (42), but the phosphorylation site is different from the SDK1 site (40).

Lys49 Is Required for Recognition of 14-3-3 by SDK1-- In the three-dimensional structure of 14-3-3 zeta , the SDK1 phosphorylation site (Ser58) is localized on helix 3, and Ser58 participates in dimerization, while Lys49 and other positively charged residues of the helix form part of an amphipathic groove involved in ligand binding (43). Consistent with the proposed role of the amphipathic groove in ligand binding, Lys49-Glu mutation disrupted ligand association but Arg60-Glu had only a small effect (32). To test whether SDK1 also uses this amphipathic groove of 14-3-3 for substrate recognition, we examined the effect of the Lys49-Glu and Arg60-Glu mutations on phosphorylation of 14-3-3 by activated SDK1. The Lys49-Glu mutation abolished the ability of 14-3-3 to serve as a SDK1 substrate, while the Arg60-Glu mutation reduced phosphorylation only by about 50% (Fig. 8A, upper panel). Equivalent quantities of 14-3-3 were used for each reaction (Fig. 8A, lower panel). These results suggest that the requirements for SDK1 recognition of 14-3-3 are the same as those for ligand binding to 14-3-3 (32). It is interesting that the mutation in Arg60 in position 2+ relative to the phosphorylation site, had much less effect than the distant Lys49 mutation in position -9. These findings suggest that direct binding of SDK1 via the amphipathic groove in 14-3-3 is required for subsequent phosphorylation at Ser58.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 8.   The amino acid Lys49 is required for recognition of 14-3-3 by SDK1. Point mutation of Lys49 but not of Arg60 abolished phosphorylation of 14-3-3 zeta  by SDK1. SDK1 was purified by Mono-Q ion exchange chromatography (step 2). The SDK1 activity toward Lys49-Glu, and Arg60-Glu mutants of 14-3-3 zeta , in comparison to native 14-3-3 zeta  (120 nM), was determined by standard SDK1 activity assay. Upper panel, autoradiogram of 12% SDS-PAGE generated from phosphorylation of various 14-3-3 zeta  mutants and wild type protein in the absence (-) or presence (+) of DMS. K49E indicates that Lys49 is mutated to Glu; R60E indicates that Arg60 is mutated to Glu. Lower panel, Coomassie Blue staining pattern of the same SDS-PAGE as in upper panel. Note that although 14-3-3 proteins were present in all reactions, only the Lys49-Glu point mutation abolished phosphorylation by SDK1.

An SDK Is Associated with 14-3-3 and Is Activated by Exogenous DMS, Leading to 14-3-3 Phosphorylation in Situ-- 14-3-3 proteins were purified together with SDK1 at the first purification step on ion-exchange chromatography. To confirm the interaction between 14-3-3 and SDK1, we tested the ability of various 14-3-3 Abs to precipitate SDK activity from cytosolic extract. The PAN, zeta , and tau  Abs raised against different epitopes of 14-3-3 isoforms were utilized. These Abs detected endogenous 14-3-3 beta , zeta , and tau  found in 3T3 cell lysates (data not shown). SDK activity was co-immunoprecipitated by PAN Ab or zeta  Ab as indicated by phosphorylation of exogenous 14-3-3 zeta  in the presence of DMS (Fig. 9A). In contrast, tau  Ab did not precipitate SDK activity together with 14-3-3, although Western blot analysis revealed a similar level of 14-3-3 proteins in all immunoprecipitates (data not shown). These results indicate a specific association of an SDK with certain isoforms of 14-3-3. It is reasonable to conclude that SDK1 is probably associated with 14-3-3 zeta  in situ, since the zeta  Ab is isoform-specific and cross-reacts only with 14-3-3 zeta  but not with 14-3-3 beta , eta , or tau .


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 9.   Association of 14-3-3 with SDK activity, and induction of in situ 14-3-3 phosphorylation in Balb/c 3T3(A31) cells incubated with DMS. Panel A, cytosolic extracts derived from 3T3(A31) cells were immunoprecipitated with PAN Ab which detects all 14-3-3 isoforms (lanes 1-4), zeta  Ab specific to 14-3-3 zeta  (lanes 5-8), or tau  Ab which detects 14-3-3 zeta  and tau  (lanes 9-12). SDK1 activity in the resulting immunocomplexes was determined in the absence (-) or presence (+) of 120 nM 14-3-3 zeta , and of 100 µM DMS delivered in 0.5% octyl-beta -glucoside as indicated at the top, and in the presence of [gamma -32P]ATP as described under "Experimental Procedures." Reaction products were analyzed by SDS-PAGE followed by autoradiography. Arrow, position of 14-3-3 zeta . Positions of molecular weight markers are indicated at left. Panel B, effect of exogenous DMS on phosphorylation of endogenous 28-kDa protein corresponding to 14-3-3. Confluent Balb/c 3T3(A31) fibroblasts were metabolically labeled with [32P]orthophosphate in serum-free medium and challenged with DMS or TPA as described under "Experimental Procedures." Cells were challenged with vehicle 0.02% ethanol (lanes 1 and 2) without DMS as negative control, 2 µM DMS (lane 3), 10 µM DMS (lane 4), or 200 nM TPA for 20 min. Cytosolic extracts were prepared from these cells, and 14-3-3 proteins were immunoprecipitated with PAN Ab. The immunoprecipitated fractions were resolved on SDS-PAGE and analyzed by Western blotting utilizing PAN Ab followed by autoradiography. Lane 1, cell extract without immunoprecipitation. Panel B, right, Western blot of the immunoprecipitated fractions. The strong heterogeneous bands in lanes 2-5 were immunoglobulin detected by secondary Ab after blotting. Panel B, left: autoradiography of the Western blot shown in panel B, right.

In order to investigate whether SDK1 is activated by DMS and subsequently phosphorylates 14-3-3 in situ, 14-3-3 proteins were immunoprecipitated from DMS-treated fibroblasts. Cells were labeled with [32P]orthophosphate in serum-free medium, and challenged with 0, 2, or 10 µM DMS in ethanol, or 200 nM TPA, for 20 min. These treatments did not affect cell viability. Phosphorylated 14-3-3 proteins were immunoprecipitated with PAN Ab. Western blotting analysis indicated equal recovery of 14-3-3 proteins after all treatments (Fig. 9B, right, lanes 2-5). Autoradiography of the same Western blot clearly reveals DMS-induced phosphorylation of a 28-kDa band corresponding to 14-3-3 (Fig. 9B, left, lanes 3 and 4). In contrast, 14-3-3 was not phosphorylated in cells treated with vehicle control or TPA (Fig. 9B, left, lanes 2 and 5, respectively). These results indicate that DMS activates an SDK, leading to phosphorylation of 14-3-3 in situ. In summary, an SDK is associated with 14-3-3 zeta  in situ, and is activated by DMS to subsequently phosphorylate 14-3-3 in intact cells. We propose that the SDK activated in situ to phosphorylate 14-3-3 is most likely SDK1, since this is the only SDK known to phosphorylate 14-3-3 in vitro.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We partially purified a sphingosine-dependent protein kinase, SDK1, that is activated by Sph or DMS but not by other lipids, and specifically phosphorylates certain isoforms of 14-3-3 protein in vitro. Sph-dependent phosphorylation of endogenous 14-3-3 proteins was previously detected in a crude system, suggesting that 14-3-3 proteins are major substrates for cellular SDK activities. Addition of DMS to Balb/c 3T3(A31) fibroblasts stimulates phosphorylation of 14-3-3 proteins, and SDK activity is associated with endogenous 14-3-3 zeta ; therefore, SDK1 may also phosphorylate 14-3-3 proteins in intact cells. The failure of SDK1 to phosphorylate PDI and calreticulin, endogenous substrates of other types of SDKs, indicates the existence of several other SDKs with distinct substrate specificity. Thus, several different kinases, including SDK1, other SDKs, and certain tyrosine kinases, may mediate signal transduction induced by Sph and DMS (2, 17, 18, 20).

SDK1 phosphorylates the eta , beta , and zeta , isoforms of 14-3-3 at Ser adjacent to Trp in the sequence Arg-Arg-Ser-Ser-Trp-Arg. 14-3-3 proteins have consensus sequences for phosphorylation by several protein kinases (41). The site phosphorylated by SDK1 fits the consensus motif for phosphorylation by PKA and PKC (41); however, PKA fails to phosphorylate 14-3-3 (40), and PKC phosphorylates a different site that is conserved in all isoforms of 14-3-3 (eta , beta , zeta , tau , and sigma ) (40, 42). 14-3-3 beta  and zeta  isolated from sheep brain are phosphorylated on Ser184 in the site Ser-Pro-Glu-Lys (44), a consensus sequence motif of proline-dependent protein kinase (41). Casein kinase I phosphorylates 14-3-3 zeta  and tau  on residue 233 (45, 46). A breakpoint cluster region protein (Bcr) phosphorylates Ser, and Bcr-Abl phosphorylates Ser and Tyr, on 14-3-3 tau  in vitro, but the phosphorylated residues have not been mapped (47).

The crystal structure of 14-3-3 at 2.9-Å resolution indicates a dimer, and each monomer contains nine helices (Fig. 10A) (43). The longest helix, helix 3, interacts with helix 1 of the opposite monomer and contributes to the dimer interface as well as the ligand binding groove. Many residues located in this helix are invariant among vertebrates, yeast, and plants (43). Mutagenesis and structural studies indicate that the surface of helix 3 that faces helix 5 forms the pocket in 14-3-3 that binds to phosphopeptide ligands of the sequence Arg-Ser-X-pSer-X-Pro (32, 43, 48, 49). However, the residue (Ser58 of 14-3-3 zeta ) that is phosphorylated by SDK1 in helix 3 of one monomer faces away from the ligand-binding pocket and toward the other monomer in the 14-3-3 dimer (Fig. 10B; Ser shown in red). This Ser is buried in the dimer interface, lying just 5.8 Å from a conserved Arg (Arg18 in 14-3-3 zeta ) of the other monomer. After phosphorylation, a negative charge on phosphoserine 58 may interact with the positive charge on the side chain of Arg18, resulting in dimer stabilization. Thus, the newly phosphorylated 14-3-3 monomer may sequester other 14-3-3 monomers, preventing monomer functions such as interaction with inactive Raf (50). The possibility described here for 14-3-3 zeta  may also apply to 14-3-3 beta  and eta , because the key residues of the dimer interface are conserved across the 14-3-3 family (43, 49).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 10.   Crystal structure of 14-3-3. Panel A, a ribbons representation of 14-3-3 zeta  dimer viewed down the molecular 2-fold axis and rotated 90° with 9 anti-paralleled helices as cylinders that form a ligand binding groove. Helix 3 of one monomer (blue) interacts with helix 1 of the second monomer (gray). SDK1 phosphorylation site is localized on the longest helix, helix 3, of one monomer (blue); Ser58 (red) is indicated. Two point mutations located on the opposite face of the helix, Arg60-Glu (green) at position +2 and Lys49-Glu (yellow) at position -9, are indicated. Panel B, 90° rotated view with enlargement of dimer interface showing that SDK1 phosphorylation site Ser58 is localized on the longest helix, helix 3, on one monomer (blue). Note that Ser58 is buried in the dimer interface forming the shortest distance from helix 1 of the opposite (gray) molecule by association with Arg18 which contributes salt bridges on the periphery.

The location of the SDK1 phosphorylation site in the dimer interface of 14-3-3 also raises the question of how SDK1 phosphorylates this buried residue. Although the recombinant 14-3-3 used during SDK1 purification may be partly monomeric, the phosphorylation of endogenous 14-3-3 proteins suggests that SDK1 or Sph can promote either dimer dissociation or conformational changes that expose the phosphorylation site. PKC may not induce such conformational changes, because PKC fails to phosphorylate the SDK1 site in native 14-3-3 but does phosphorylate this site in a peptide substrate (40).

All protein kinases interact via their catalytic pocket with the phosphoaccepting hydroxyamino acid, as well as with several specificity conferring residues that flank the phosphoacceptor site (51). Substrate recognition by SDK1 was investigated using mutants Lys49-Glu (Fig. 10B, yellow) and Arg60-Glu (green). Lys49, which is located nine amino acids (2.5 helix turns) from the phosphorylation site, facing the opposite side of helix 3 (43), had a surprisingly large effect on phosphorylation by SDK1. On the other hand, Arg60-Glu mutation, located 2 amino acids C-terminal to the phosphorylation site, reduced phosphorylation by only 50%, suggesting that the positive charge of Arg60 has little effect on SDK1 activity. Lys49 faces the proposed 14-3-3 ligand binding groove (32). The requirement for a functional binding groove in 14-3-3, and the lack of a strong requirement for a residue close to the phosphorylation site, suggest that the molecular interactions mediating binding of SDK1 to 14-3-3 are not typical of most protein kinases and their substrates.

Sph is generated from sphingolipid degradation in the plasma membrane, and can be transferred to other intracellular membrane compartments. However, Sph traffic into the soluble phase of the cytoplasm has not been investigated. The majority of SDK1 activity is in the cytosol, but it is not clear whether the Sph that activates SDK1 is in the membrane or cytosol. SDK1 may be activated by translocation to the membrane, since 14-3-3 zeta  is associated with SDK1 in situ, and partially purified membrane SDKs phosphorylate 14-3-3 (21). In addition, 14-3-3 proteins, which are found in cytosol, are also associated with the plasma membrane (52), and can promote translocation of kinases to different cellular compartments upon stimulation with agonists. For example, serum stimulation translocates KSR-14-3-3 zeta  complex from cytosol to membrane, resulting in association with Raf-1 and activation (29). In contrast, the eta  and tau  isoforms promote translocation from cytoskeleton to cytosol of A20 and PKC theta , respectively (53, 54). The tau  isoform inhibits PKC theta by preventing its translocation to membrane (54). Because SDK1 is associated with 14-3-3, association of 14-3-3 with membrane could also provide a means for activation of SDK1 by membrane-bound Sph.

We used DMS to demonstrate Sph-dependent phosphorylation of 14-3-3 in situ, since in fibroblasts this Sph derivative cannot be phosphorylated or modified to create other potential kinase activators. DMS and Sph are found naturally in cells, and enzymes that convert Sph to DMS have been detected in tissues, suggesting that DMS is a physiological activator (15, 16, 55). A relatively low concentration of exogenous DMS (2 µM) induced rapid phosphorylation of 14-3-3 in intact cells. The rapid penetration of Sph or DMS into platelets (56) and the fact that 80% of DMS is incorporated in A31 cells within 5 min (data not shown) suggest an intracellular activation of SDK1 by Sph or DMS. Extracellular agonists such as platelet-derived growth factor and insulin-like growth factor, which increase Sph levels within the cell, may also stimulate 14-3-3 phosphorylation. Further studies are needed to correlate phosphorylation of eta , beta , and zeta  isoforms of 14-3-3 (SDK1 substrates) with the increase of intracellular Sph levels induced by growth factors. Such studies would shed light on the regulatory role of Sph and SDK1 activity in intracellular signaling via modulation of the function of specific 14-3-3 isoforms.

    ACKNOWLEDGEMENTS

We thank Dr. Kimie Murayama and Tsutomu Fujimura for preparation of hexadecapeptide, Dr. Edwin Krebs for the gift of anti-CKII Ab, Dr. Ari Helenius for the gift of calreticulin, Dr. Yasuyuki Igarashi for helpful discussions, Melissa Jurica and Dr. Barry Stoddard for computer assistance, Dr. R. Liddington for coordinates, and Dr. Stephen Anderson for scientific editing and preparation of the manuscript.

    FOOTNOTES

* This work was supported in part by National Cancer Institute Outstanding Investigator Grant CA42505 (to S. H.) and National Institutes of Health Grants CA54786 (to J. C.) and GM53165 (to H. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel Burroughs Wellcome Fund New Investigator.

** To whom correspondence should be addressed. E-mail: hakomori{at}u.washington.edu.

The abbreviations used are: Sph, sphingosine; Ab, antibody; AEBSF, 4-(2-aminoethyl)-benzenesulfonyl fluoride; CKII, casein kinase II; DAG, diacylglycerol; DMS, N,N'-dimethylsphingosineDTT, dithiothreitolErk, extracellular signal-regulated mitogene-activated protein kinaseFBS, fetal bovine serumFT, flow-throughKSR, kinase suppressor of rasNC, nitrocellulosePDI, protein disulfide isomerasePKA, protein kinase APKC, protein kinase CPKM, catalytic domain of protein kinase CPS, L-alpha -phosphatidyl-L-serineSDK, sphingosine-dependent protein kinaseSph-1-P, sphingosine 1-phosphateTPA, 12-O-tetradecanoylphorbol-13-acetatePAGE, polyacrylamide gel electrophoresisDMEM, Dulbecco's modified Eagle's mediumMOPS, 4-morpholinepropanesulfonic acid.

2 R. R. Subrumanian, S. C. Masters, and H. Fu, manuscript in preparation.

3 T. Megidish, K. Takio, K. Titani, Y. Igarashi, A. Helenius, and S. Hakomori, manuscript in preparation.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Hakomori, S. (1990) J. Biol. Chem. 265, 18713-18716[Abstract/Free Full Text]
  2. Spiegel, S., and Milstien, S. (1995) J. Membr. Biol. 146, 225-237[Medline] [Order article via Infotrieve]
  3. Hannun, Y. A., and Linardic, C. M. (1993) Biochim. Biophys. Acta 1154, 223-236[Medline] [Order article via Infotrieve]
  4. Merrill, A. H. J., and Stevens, V. L. (1989) Biochim. Biophys. Acta 1010, 131-139[Medline] [Order article via Infotrieve]
  5. Spiegel, S., Foster, D., and Kolesnick, R. N. (1996) Curr. Opin. Cell Biol. 8, 159-167[CrossRef][Medline] [Order article via Infotrieve]
  6. Hannun, Y. A., Loomis, C. R., Merrill, A. H., Jr., and Bell, R. M. (1986) J. Biol. Chem. 261, 12604-12609[Abstract/Free Full Text]
  7. Igarashi, Y., Hakomori, S., Toyokuni, T., Dean, B., Fujita, S., Sugimoto, M., Ogawa, T., El-Ghendy, K., and Racker, E. (1989) Biochemistry 28, 6796-6800[Medline] [Order article via Infotrieve]
  8. Jefferson, A. B., and Schulman, H. (1988) J. Biol. Chem. 263, 15241-15244[Abstract/Free Full Text]
  9. Arnold, R. S., and Newton, A. C. (1991) Biochemistry 30, 7747-7754[Medline] [Order article via Infotrieve]
  10. McDonald, O. B., Hannun, Y. A., Reynolds, C. H., and Sahyoun, N. (1991) J. Biol. Chem. 266, 21773-21776[Abstract/Free Full Text]
  11. Igarashi, Y., Kitamura, K., Toyokuni, T., Dean, B., Fenderson, B., Ogawa, T., and Hakomori, S. (1990) J. Biol. Chem. 265, 5385-5389[Abstract/Free Full Text]
  12. Abdel-Ghany, M., Osusky, M., Igarashi, Y., Hakomori, S., Shalloway, D., and Racker, E. (1992) Biochim. Biophys. Acta 1137, 349-355[Medline] [Order article via Infotrieve]
  13. Coroneos, E., Martinez, M., McKenna, S., and Kester, M. (1995) J. Biol. Chem. 270, 23305-23309[Abstract/Free Full Text]
  14. Ohta, H., Sweeney, E. A., Masamune, A., Yatomi, Y., Hakomori, S., and Igarashi, Y. (1995) Cancer Res. 55, 691-697[Abstract]
  15. Igarashi, Y., and Hakomori, S. (1989) Biochem. Biophys. Res. Commun. 164, 1411-1416[Medline] [Order article via Infotrieve]
  16. Mano, N., Oda, Y., Yamada, K., Asakawa, N., and Katayama, K. (1997) Anal. Biochem. 244, 291-300[CrossRef][Medline] [Order article via Infotrieve]
  17. Seufferlein, T., and Rozengurt, E. (1994) J. Biol. Chem. 269, 27610-27617[Abstract/Free Full Text]
  18. Blakesley, V. A., Beitner-Johnson, D., Van Brocklyn, J. R., Rani, S., Shen-Orr, Z., Stannard, B. S., Spiegel, S., and LeRoith, D. (1997) J. Biol. Chem. 272, 16211-16215[Abstract/Free Full Text]
  19. Zhang, H., Buckley, N. E., Gibson, K., and Spiegel, S. (1990) J. Biol. Chem. 265, 76-81[Abstract/Free Full Text]
  20. Pushkareva, M. Yu., Khan, W. A., Alessenko, A. V., Sahyoun, N., and Hannun, Y. A. (1992) J. Biol. Chem. 267, 15246-15251[Abstract/Free Full Text]
  21. Megidish, T., White, T., Takio, K., Titani, K., Igarashi, Y., and Hakomori, S. (1995) Biochem. Biophys. Res. Commun. 216, 739-747[CrossRef][Medline] [Order article via Infotrieve]
  22. Hunter, T. (1995) Cell 83, 1-4[Medline] [Order article via Infotrieve]
  23. Nishizuka, Y. (1995) FASEB J. 9, 484-496[Abstract/Free Full Text]
  24. Morrison, D. K. (1995) Mol. Reprod. Dev. 42, 507-514[Medline] [Order article via Infotrieve]
  25. Aitken, A. (1996) Trends Cell Biol. 6, 341-347[CrossRef]
  26. Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H. (1997) Science 277, 1501-1505[Abstract/Free Full Text]
  27. Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J. (1996) Cell 87, 619-628[Medline] [Order article via Infotrieve]
  28. Morrison, D. (1994) Science 266, 56-57[Medline] [Order article via Infotrieve]
  29. Xing, H., Kornfeld, K., and Muslin, A. J. (1997) Curr. Biol. 7, 294-300[Medline] [Order article via Infotrieve]
  30. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241[Medline] [Order article via Infotrieve]
  31. Radunz, H.-E., Devant, R. M., and Eiermann, V. (1988) Liebigs Ann. Chem. 1103-1105
  32. Zhang, L., Wang, H., Liu, D., Liddington, R., and Fu, H. (1997) J. Biol. Chem. 272, 13717-13724[Abstract/Free Full Text]
  33. Rodriguez-Pena, A., and Rozengurt, E. (1984) Biochem. Biophys. Res. Commun. 120, 1053-1059[Medline] [Order article via Infotrieve]
  34. Lavie, Y., Blusztajn, J. K., and Liscovitch, M. (1994) Biochim. Biophys. Acta 1220, 323-328[Medline] [Order article via Infotrieve]
  35. Hannun, Y. A., Loomis, C. R., and Bell, R. M. (1985) J. Biol. Chem. 260, 10039-10043[Abstract/Free Full Text]
  36. Litchfield, D. W., Lozeman, F. J., Piening, C., Sommercorn, J., Takio, K., Walsh, K. A., and Krebs, E. G. (1990) J. Biol. Chem. 265, 7638-7644[Abstract/Free Full Text]
  37. Boyle, W. J., van der Geer, P., and Hunter, T. (1991) Methods Enzymol. 201, 110-149[Medline] [Order article via Infotrieve]
  38. Watanabe, M., Isobe, T., Ichimura, T., Kuwano, R., Takahashi, Y., Kondo, H., and Inoue, Y. (1994) Mol. Brain Res. 25, 113-121[Medline] [Order article via Infotrieve]
  39. Perego, L., and Berruti, G. (1997) Mol. Reprod. Dev. 47, 370-379[CrossRef][Medline] [Order article via Infotrieve]
  40. Toker, A., Sellers, L. A., Amess, B., Patel, Y., Harris, A., and Aitken, A. (1992) Eur. J. Biochem. 206, 453-461[Abstract]
  41. Kennelly, P. J., and Krebs, E. G. (1991) J. Biol. Chem. 266, 15555-15558[Free Full Text]
  42. Aitken, A., Howell, S., Jones, D., Madrazo, J., Martin, H., Patel, Y., and Robinson, K. (1995) Mol. Cell. Biochem. 149/150, 41-49
  43. Liu, D., Bienkowska, J., Petosa, C., Collier, R. J., Fu, H., and Liddington, R. (1995) Nature 376, 191-194[CrossRef][Medline] [Order article via Infotrieve]
  44. Aitken, A., Howell, S., Jones, D., Madrazo, J., and Patel, Y. (1995) J. Biol. Chem. 270, 5706-5709[Abstract/Free Full Text]
  45. Rommel, C., Radziwill, G., Lovric, J., Noeldeke, J., Heinicke, T., Jones, D., Aitken, A., and Moelling, K. (1996) Oncogene 12, 609-619[Medline] [Order article via Infotrieve]
  46. Dubois, T., Rommel, C., Howell, S., Steinhussen, U., Soneji, Y., Morrice, N., Moelling, K., and Aitken, A. (1997) J. Biol. Chem. 272, 28882-28888[Abstract/Free Full Text]
  47. Reuther, G. W., Fu, H., Cripe, L. D., Collier, R. J., and Pendergast, A. M. (1994) Science 266, 129-133[Medline] [Order article via Infotrieve]
  48. Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., Gamblin, S. J., Smerdon, S. J., and Cantley, L. C. (1997) Cell 91, 961-971[Medline] [Order article via Infotrieve]
  49. Xiao, B., Smerdon, S. J., Jones, D. H., Dodson, G. G., Soneji, Y., Aitken, A., and Gamblin, S. J. (1995) Nature 376, 188-191[CrossRef][Medline] [Order article via Infotrieve]
  50. Luo, Z., Zhang, X., Rapp, U., and Avruch, J. (1995) J. Biol. Chem. 270, 23681-23687[Abstract/Free Full Text]
  51. Taylor, S. S., Radzio-Andzelm, E., and Hunter, T. (1995) FASEB J. 9, 1255-1266[Abstract/Free Full Text]
  52. Martin, H., Rostas, J., Patel, Y., and Aitken, A. (1994) J. Neurochem. 63, 2259-2265[Medline] [Order article via Infotrieve]
  53. Vincenz, C., and Dixit, V. M. (1996) J. Biol. Chem. 271, 20029-20034[Abstract/Free Full Text]
  54. Meller, N., Liu, Y.-C., Collins, T. L., Bonnefoy-Berard, N., Baier, G., Isakov, N., and Altman, A. (1996) Mol. Cell. Biol. 16, 5782-5791[Abstract]
  55. Kobayashi, T., Mitsuo, K., and Goto, I. (1988) Eur. J. Biochem. 172, 747-752[Abstract]
  56. Yatomi, Y., Ozaki, Y., Satoh, K., Kume, S., Ruan, F., and Igarashi, Y. (1997) Biochem. Biophys. Res. Commun. 231, 848-851[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.